A Phase 2 interventional study of TEV-56286 in Multiple System Atrophy, sponsored by Teva Branded Pharmaceutical Products R&D LLC. Recruiting at 36 sites in 7 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Teva Branded Pharmaceutical Products R&D LLC · Phase 2, Interventional, and Treatment
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).
A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286.
The planned total duration of the trial is approximately 100 weeks.
NOTE - Additional criteria apply, please contact the investigator for more information
Exclusion Criteria:
Note - Additional criteria apply, please contact the investigator for more information
Drug: TEV-56286
administered orally
Also known as: Emrusolmin
Number of participants experiencing an adverse event
Time frame: Baseline to Week 100
Number of participants who withdrew from the trial due to an adverse event
Time frame: Baseline to Week 100
Number of participants with potentially clinically significant vital sign values
Time frame: Baseline to Week 96
Number of participants with potentially clinically significant laboratory test values (hematology and chemistry)
Time frame: Baseline to Week 96
Number of participants with potentially clinically significant 12-lead ECG measurements
Time frame: Baseline to Week 96
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Teva Branded Pharmaceutical Products R&D LLC